Fig. 2.

The nitroalkene analogs CP-8 and CP-23 exhibit differential growth inhibition of cancer and normal cells. A. MDA-MB-231, B. hTERT HME1, C. MCF10A or D. MDA-MB-231, MDA-MB-468, MCF-10 plated subconfluently (5 × 10²) and confluently (5 × 10³), E. 4T1 cells were plated in a 96-well plate (500 cells/well) and dosed with 0–6 μM nitroalkene analogs on days 0, 2 and 6. Growth inhibition was determined by measuring relative ATP levels on day 7 via CellTiter-Glo (Average ± SEM n = 3 except for CP-27 to CP-30 (n = 1)).